Abstract
Background: Proliferation is a distinct hallmarks of cancer. Ki-67 designated as a marker of proliferation in solid tumors. The proliferative activity of tumor demonstrated by expression of Ki-67 in breast cancer has been associated with a poor prognosis. Changes in the relative proportions of Ki-67 can be observed during chemotherapy and may correlated with clinical response in breast cancer. Purpose: Evaluate changes in mRNA expression of proliferation marker Ki-67 in breast cancer patients pre- and post-chemotherapy in relation with clinical response to chemotherapy. Method: This is a longitudinal study, 30 subjects breast cancer tissue samples pre- and post-chemotherapy using cyclophosphamide, adriamycin, 5FU regiment. We using qRT-PCR techniques to detect mRNA expression of Ki-67. Chemotherapy response is calculated using RECIST criteria. Results: Mean value of Ki-67 mRNA expression on breast cancer patients pre-chemotheraphy was 11.837±0.360. Mean value of Ki-67 mRNA expression on breast cancer patients post-chemotheraphy was 11.241±1.971. There was no significant correlation between expression of Ki-67 mRNA prechemotherapy with clinical response to chemotherapy, p = 0.862 (<i>p</i> ≥0.05). There is a positive correlation between velocity of Ki-67 mRNA expression with clinical response with value of r = 0.378, this correlation was significant with <i>p</i> = 0.020 (<i>p</i><0.05). Conclusion: Chemotherapy cause decrease in mRNA expression of Ki-67. There is insignificant correlation between expression of mRNA Ki-67 baseline with chemotherapy response. Velocity of Ki-67 mRNA expression has significant correlation with clinical response to chemotherapy.
Highlights
Proliferation has been recognized as a distinct hallmark of cancer [1]
Some Studies reveal that mRNA expression of Ki-67 seems to be more robust and meaningful than the determination based on the Ki-67 protein by immunohistochemistry, either by visual scoring or quantitative image analysis [6]
There was no significant correlation between expression of Ki-67 mRNA prechemotherapy with clinical response to chemotherapy, p = 0.862(p ≥0.05)
Summary
Proliferation has been recognized as a distinct hallmark of cancer [1]. Ki-67 is a core protein that is expressed on the cell being proliferated and the level of expression changes throughout the cell cycle [2]. Several studies have found changes in the expression of Ki-67 pre- and postchemotherapy become a strong and independent predictor of the disease-free period and survival. This is the reason that the tumor response in many neoadjuvant chemotherapy trials are evaluated by examination of Ki-67 in immunohistochemistry [4]. The aim of this study was to evaluate mRNA expression of Ki-67 pre- and American Journal of Clinical and Experimental Medicine 2017; 5(1): 10-14 post-chemotherapy in associations with breast cancer chemotheraphy response. Purpose: Evaluate changes in mRNA expression of proliferation marker Ki-67 in breast cancer patients pre- and post-chemotherapy in relation with clinical response to chemotherapy. Velocity of Ki-67 mRNA expression has significant correlation with clinical response to chemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Clinical and Experimental Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
